Owl Therapeutics

Owl Therapeutics is a wholly-owned subsidiary of Gryphon Bio​ that is dedicated to unlocking wisdom for brain health. Specializing in the development of diagnostic-powered therapeutics for traumatic brain injury (TBI) and brain health, Owl Therapeutics has rapidly constructed a diversified pipeline of small and large molecule medicines to address the unmet needs of patients suffering from neurodegenerative diseases. Established in 2023, the company operates in the Biopharma sector and is headquartered in the United States. It is helmed by a proven, cohesive, interdisciplinary, and internationally recognized team with extensive scientific, clinical, and business experience in drug development and commercialization. Currently, there is no publicly disclosed information about the latest investment or specific investors.